Current therapeutic approaches for patients with myelodysplastic syndromes.

doi:10.1111/j.1365-2141.2010.08226.x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Current therapeutic approaches for patients with myelodysplastic syndromes.

British journal of haematology - 1 Jul 2010

Greenberg Peter L

Abstract excerpt

The myelodysplastic syndromes (MDS) are a heterogeneous spectrum of disorders requiring selective therapy based on patients' specific clinical features, predominantly their prognostic subgroups, age and performance status. Guidelines for management of patients with MDS have been generated by a number of national panels. This review focuses on evidence-based data supporting therapeutic approaches, which have also...

Topics

Antineoplastic Agents
Drug Costs
Humans
Iron Chelating Agents
Mutation
Myelodysplastic Syndromes
Practice Guidelines as Topic
Prognosis
Quality of Life

Source

Open in PubMed

Identifiers

PMID: 20507314
DOI: 10.1111/j.1365-2141.2010.08226.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics